It was demonstrated that the oral vaccine application of Salmonella typhi antigen can activate low antibody agglutinin titer (mean:40±0) comparing with high agglutination titer induced by Intramuscular administration of Salmonella typhi antigen (mean 560.0 ± 51.64) as well as anti-Salmonella typhi IgG ELIZA shows high mean index value(mean = 0.6957±0.10) comparing with the low index value induced by oral rout were (mean= 0.028±0.014) while anti Salmonella typhi IgM ELIZA test show mean index value = 0.6339±0.0385 comparing with low IgM index value (mean= 0.1560±0.070) induced by oral rout (Rsquared 0.7457, t test 3.3. The pro –inflammatory cytokines IL-1α was high in intramuscular rout 217.089±39.78 than its concentration with in oral administrated group (100.4±12.09), IL-12 was about the same concentration both in oral rout and intramuscular rout subsequently (23.607 and 23.17) p value 0.01, R squared (0.3958).However the immune responses were not absolutely absent in the oral administrated group, this reflect the fact that there is a selectivity in taking oral antigens from digestive mucosal surfaces but this immune feature and selectivity theme may vary from antigen to another. In conclusion the recent and ongoing expansion of a new information about the mucosal and systemic immune responses lend a promise to provide the tools needed to exploit the full potential and development of both mucosal and intramuscular vaccines.
Published in |
American Journal of Biomedical and Life Sciences (Volume 3, Issue 4-1)
This article belongs to the Special Issue Advances in Oral Immunity |
DOI | 10.11648/j.ajbls.s.2015030401.15 |
Page(s) | 13-16 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
Oral Tolerance, Systemic Immune Response, Intramuscular Rout
[1] | Kaufmann, H, E,S; Rouse, B, T, Sacks, D.L. 2011. The Immune Response to Infection. ASM, USA. pp:105. |
[2] | Neutra M R, Kraenebahl J – P,1996,Antigen uptake by M cell for effective mucosal response, In Kiyono H, Ogra PL, McGee J R, eds, Mucosal Vaccines, Academic Press,London,3-14. |
[3] | Oleszewska W, Openshaw PJM ,2004,Mucosal VaccinesIn Kauffmann ed, Novel Vaccine Strategies,Wiley,VCH,Verlag,GmbH&Co.,KGaA,Germany,343-359. |
[4] | Staats H F, McGee JR1996 ,Principles of Mucosal Vaccination. In, Kiyono H, Ogra P L, McGee, J R, eds, Mucosal Vaccines, Academic Press, London, 15- 33. |
[5] | Ogra P L ,1996,Mucosal Immunoprophlaxis: An introductory overview, In, Kiyono H, Ogra P L, McGee J R, eds, Mucosal Vaccines, Academic Press,London,3-14. |
[6] | Ogra P L, Faden Hand Welliver R C.2001. Vaccination Strategies for Mucosal Immune Responses. ClinMicrobiol Rev. 2001 Apr; 14(2): 430–445. |
[7] | Marth T, Strober W, Kelsall BL. 1996.High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J Immunol. 15;157(6):2348-57. |
[8] | Willey J, Sherwood L, Woolverton C. 2008. Microbiology 7th ed. Prescott Harley &Kleins McGraw-Hill. |
[9] | Svanborg E C, Kulhavy R, Marlid S, Prince S Jand Mestecky J.1985. Urinary immunoglobulins in healthy individuals and children with acute pyelonephritis. Scand .J. Immunol.,305-313. |
[10] | Steven C D. 2010. Clinical Immunology and Serology: A Laboratory Perspective,3edFA Davis Company, Philadelphia. |
[11] | Marie-Christiane M, Valerie G R. 2001. Influence of Resident Intestinal Micro oral on the Development and Functions of the Gut-Associated Lymphoid Tissue. Microbial Ecology in Health and Disease. 13: 65–86. |
[12] | Herman F. Staats and Francis A. Ennis, Jr. 1999. IL-1 Is an Effective Adjuvant for Mucosal and Systemic Immune Responses When Coadministered with Protein Immunogens1, Herman F. Staats2 and Francis A. Ennis, Jr. The Journal of Immunology. 162: 6141–6147. |
[13] | Weiner HL. 2001. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 3(11):947-54. |
[14] | Jiri M, Zina M, Charles O E. 2005. Immune response versus mucosal tolerance to mucosally administered antigens. J. Vaccine 23:1800–1803. |
[15] | -Barone K S, Tolarova D D, Ormsby I, Doetschman T, Michael J G. 1998. Induction of oral tolerance in TGF-β1 null mice. J Immunol. 161:154–160. |
[16] | Mowat A M, Weiner H L. Oral tolerance: physiological basis and clinical applications.1999. In: Ogra P L, Mestecky J, Lamm M E, Strober W, Bienenstock J, McGhee J R, editors. Mucosal immunology. 2nd ed. New York, N.Y: Academic Press; pp. 587–618. |
[17] | Mason KL, Huffnagle GB, Noverr MC, Kao JY. 2008. Overview of gut immunology. AdvExp Med Biol. 2008; 635:1-14. doi: 10.1007/978-0-387-09550-9_1. |
[18] | Jasvir S J, Mark J P ,Suman G, Laura K. Phillip W. Marry E B, and Steven D L, Lucill L. 2012. Salivary glands act as mucosal inductive sites via the formation of ectopic germinal centers after site-restricted MCMV infection. J.FASEB, 25(5): 1680-1696. |
[19] | Weigle W O, 1998, Immune Tolerance Model, In.Delves P J and Roitt I M ed. Encyclopedia of Immunology 2d ed , Vol.4, Academic Press, New York, 2359-2361. |
[20] | Jiang X, Nicolls M R, 2014, Working towards immune tolerance in lung transplantation, J. Clin. Invest., 124(3)967-970. |
[21] | Kubn C, You S, Valette F, Endert P V, Bach J-F, Waldmann H, Chatenoud L. 2011, Human CD3 transgenic mice: Preclinical testing of antibodies promoting immunological tolerance, Translat. Med, 3(68):678-78. |
[22] | Shnawa IMS. 2015. Oral mucosal immune tolerance versus oral immune silenceing: Minireview, Am. J. Biomed. Lif. Sci. 3(4-1)7-9. |
APA Style
Ibrahim Mohamed Saeed Shnawa, Zainab Khudhur Ahmed Al-Mahdi. (2015). Oral Mucosal Tolerance Versus Systemic Immune Response to Salmonella typhi Antigen. American Journal of Biomedical and Life Sciences, 3(4-1), 13-16. https://doi.org/10.11648/j.ajbls.s.2015030401.15
ACS Style
Ibrahim Mohamed Saeed Shnawa; Zainab Khudhur Ahmed Al-Mahdi. Oral Mucosal Tolerance Versus Systemic Immune Response to Salmonella typhi Antigen. Am. J. Biomed. Life Sci. 2015, 3(4-1), 13-16. doi: 10.11648/j.ajbls.s.2015030401.15
AMA Style
Ibrahim Mohamed Saeed Shnawa, Zainab Khudhur Ahmed Al-Mahdi. Oral Mucosal Tolerance Versus Systemic Immune Response to Salmonella typhi Antigen. Am J Biomed Life Sci. 2015;3(4-1):13-16. doi: 10.11648/j.ajbls.s.2015030401.15
@article{10.11648/j.ajbls.s.2015030401.15, author = {Ibrahim Mohamed Saeed Shnawa and Zainab Khudhur Ahmed Al-Mahdi}, title = {Oral Mucosal Tolerance Versus Systemic Immune Response to Salmonella typhi Antigen}, journal = {American Journal of Biomedical and Life Sciences}, volume = {3}, number = {4-1}, pages = {13-16}, doi = {10.11648/j.ajbls.s.2015030401.15}, url = {https://doi.org/10.11648/j.ajbls.s.2015030401.15}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.s.2015030401.15}, abstract = {It was demonstrated that the oral vaccine application of Salmonella typhi antigen can activate low antibody agglutinin titer (mean:40±0) comparing with high agglutination titer induced by Intramuscular administration of Salmonella typhi antigen (mean 560.0 ± 51.64) as well as anti-Salmonella typhi IgG ELIZA shows high mean index value(mean = 0.6957±0.10) comparing with the low index value induced by oral rout were (mean= 0.028±0.014) while anti Salmonella typhi IgM ELIZA test show mean index value = 0.6339±0.0385 comparing with low IgM index value (mean= 0.1560±0.070) induced by oral rout (Rsquared 0.7457, t test 3.3. The pro –inflammatory cytokines IL-1α was high in intramuscular rout 217.089±39.78 than its concentration with in oral administrated group (100.4±12.09), IL-12 was about the same concentration both in oral rout and intramuscular rout subsequently (23.607 and 23.17) p value 0.01, R squared (0.3958).However the immune responses were not absolutely absent in the oral administrated group, this reflect the fact that there is a selectivity in taking oral antigens from digestive mucosal surfaces but this immune feature and selectivity theme may vary from antigen to another. In conclusion the recent and ongoing expansion of a new information about the mucosal and systemic immune responses lend a promise to provide the tools needed to exploit the full potential and development of both mucosal and intramuscular vaccines.}, year = {2015} }
TY - JOUR T1 - Oral Mucosal Tolerance Versus Systemic Immune Response to Salmonella typhi Antigen AU - Ibrahim Mohamed Saeed Shnawa AU - Zainab Khudhur Ahmed Al-Mahdi Y1 - 2015/04/23 PY - 2015 N1 - https://doi.org/10.11648/j.ajbls.s.2015030401.15 DO - 10.11648/j.ajbls.s.2015030401.15 T2 - American Journal of Biomedical and Life Sciences JF - American Journal of Biomedical and Life Sciences JO - American Journal of Biomedical and Life Sciences SP - 13 EP - 16 PB - Science Publishing Group SN - 2330-880X UR - https://doi.org/10.11648/j.ajbls.s.2015030401.15 AB - It was demonstrated that the oral vaccine application of Salmonella typhi antigen can activate low antibody agglutinin titer (mean:40±0) comparing with high agglutination titer induced by Intramuscular administration of Salmonella typhi antigen (mean 560.0 ± 51.64) as well as anti-Salmonella typhi IgG ELIZA shows high mean index value(mean = 0.6957±0.10) comparing with the low index value induced by oral rout were (mean= 0.028±0.014) while anti Salmonella typhi IgM ELIZA test show mean index value = 0.6339±0.0385 comparing with low IgM index value (mean= 0.1560±0.070) induced by oral rout (Rsquared 0.7457, t test 3.3. The pro –inflammatory cytokines IL-1α was high in intramuscular rout 217.089±39.78 than its concentration with in oral administrated group (100.4±12.09), IL-12 was about the same concentration both in oral rout and intramuscular rout subsequently (23.607 and 23.17) p value 0.01, R squared (0.3958).However the immune responses were not absolutely absent in the oral administrated group, this reflect the fact that there is a selectivity in taking oral antigens from digestive mucosal surfaces but this immune feature and selectivity theme may vary from antigen to another. In conclusion the recent and ongoing expansion of a new information about the mucosal and systemic immune responses lend a promise to provide the tools needed to exploit the full potential and development of both mucosal and intramuscular vaccines. VL - 3 IS - 4-1 ER -